Research

Hormonal

Incretin therapies (semaglutide, tirzepatide) achieve MASH resolution and fibrosis improvement primarily through substantial, dose-dependent weight loss.

Semaglutide (2.4 mg weekly) and tirzepatide are weekly injections that reduce liver fat and inflammation by driving significant weight loss. They are highly effective for MASH resolution.

GoodSupportsHIGH confidence
incretins as weight-centric, pleiotropic agents... tirzepatide achieved both endpoints with large, dose-related weight loss.
Amirah A Alzaki et al. · Cureus · 2026

Why this rating

Supported by Phase 2/3 RCTs (ESSENCE, SYNERGY-NASH).

Source

THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty

Amirah A Alzaki et al. · Cureus · 2026

DOI 10.7759/cureus.106038

systematic_review · n=3796
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →